PTC Therapeutics (PTCT) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $186.7M–$187M, with strong execution, robust cash position, and key regulatory submissions including NDAs for sepiapterin and Translarna, and BLA for Upstaza.

• Net loss for Q2 2024 narrowed to $99.2M from $198.9M in Q2 2023, reflecting lower R&D and SG&A expenses and no intangible asset impairments.

• Royalty revenue from Evrysdi increased 44% year-over-year to $53.2M, driven by higher global sales.

• Portfolio expanded with positive interim data from PTC518 PIVOT-HD study and continued progress on late-stage programs.

• Sale of gene therapy manufacturing business completed, receiving $27.5M upfront and reducing ongoing expenses.

Financial highlights

• Q2 2024 total revenue was $186.7M–$187M, with DMD franchise contributing $118M.

• Emflaza net product revenue was $47.3M–$70M; Translarna net product revenue was $47M–$70.4M.

• Royalty revenue from Evrysdi was $53.2M–$53.5M, up from $36.9M year-over-year.

• Operating expenses for Q2 2024 were $226.9M, down from $423.4M in Q2 2023.

• Cash, cash equivalents, and marketable securities totaled $1.09B as of June 30, 2024.

Outlook and guidance

• 2024 total revenue guidance raised to $700M–$750M, driven by product sales and royalty growth.

• Operating expense guidance for 2024 remains unchanged; GAAP R&D and SG&A projected at $740M–$835M.

• Up to $90M in milestone payments anticipated for 2024, with $65M as R&D expenses.

• Preparations underway for global launch of sepiapterin in 2025, with regulatory submissions planned in multiple countries.

• Cash flows from product sales, royalties, and liquidity expected to fund operations for at least the next twelve months.